XenoPort, Inc. To Present New Data Analyses For HORIZANT (gabapentin enacarbil) At The 67th Annual Meeting Of The American Academy of Neurology

SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present pooled post-hoc analyses for gabapentin enacarbil, the active ingredient in HORIZANT® (gabapentin enacarbil) Extended-Release Tablets, at the upcoming 67th Annual Meeting of the American Academy of Neurology in Washington, DC.

Help employers find you! Check out all the jobs and post your resume.

Back to news